T hyroid diseases and anemia are common disorders, and their prevalence increases with age (1) (2) (3) (4) . Hypothyroidism and anemia can each cause nonspecific symptoms of ill health like fatigue, and both lead to decreased quality of life. The combination of anemia and abnormal thyroid function may therefore be accompanied by serious morbidity and further effects on quality of life.
The co-occurrence of anemia and hypothyroidism is not only a challenging diagnostic problem in allocating symptoms to one of the diseases, but may also point to a causal relationship between thyroid disease and anemia (5) . Indeed, relationships between thyroid disease and anemia have already been documented in experimental animal studies in the distant past (5) . For instance, hypophysectomized mammals were found to have decreased red blood cell counts that corrected after administration of thyroid hormones (6, 7) . Additionally, mice deficient in the thyroid hormone receptor TRa have been found to have decreased hematocrit values (8) .
However, human data regarding relationships between thyroid disease and hematologic anomalies are scarce. Researchers investigating potential altered erythropoiesis as a result of thyroid dysfunction found red cell abnormalities and a reduced proliferative potential of hematopoietic progenitor cells in both patients with hypothyroidism and hyperthyroidism, but the total number of studied participants was low (9, 10) .
In addition, a higher prevalence of anemia was identified in older male patients with subclinical hypothyroidism (11) and in patients with clinical hypothyroidism (12) , but incidence estimates were not available due to the cross-sectional study design. Additionally, a rise of thyroid hormone levels or a decrease in levels of TSH within the reference ranges was associated with higher erythropoietic activity (13) , but the low number of studied participants precluded stratification by hyperthyroid subgroups. In one population-based cohort, both hypothyroidism and hyperthyroidism were associated with decreased hemoglobin in cross-sectional analyses but not in longitudinal analyses (14) .
Clinical experimental evidence on the causal relation between low thyroid function and anemia is currently limited to a number of small case series in which treatment of hypothyroidism with levothyroxine resulted in a considerable increase in hemoglobin and resolution of anemia (12, 15, 16) . Alternatively, and in line with the observational data, in a cohort of patients with hyperthyroidism, a high prevalence of anemia was found, which returned to normal following antithyroid therapy (17) .
Despite the myriad of smaller studies hinting at a potential relationship between thyroid dysfunction and anemia, methodologically sound pooled estimates drawn from large and representative populations are missing. In the current study, we sought to determine the association between thyroid hormone status and anemia in crosssectional and longitudinal analyses by performing an individual participant data meta-analysis on data from 16 independent observational cohort studies participating in the Thyroid Studies Collaboration.
Methods

Study population
We performed an individual participant data meta-analysis of cohorts participating in the Thyroid Studies Collaboration. The cohorts are summarized in Table 1 and described elsewhere in detail (2, (18) (19) (20) (21) . For the current project, we included the 16 cohorts in which thyroid function tests and hemoglobin were measured at baseline. 
Thyroid function
TSH and free T4 concentrations were measured at baseline in all cohorts. Cohort-specific cutoff values were applied for free T4 concentrations (Supplemental Table 1 ). Participants with a TSH level of 0.45 to 4.5 mIU/L were categorized as euthyroid. Overt hypothyroidism was defined as a TSH level .4.5 mIU/L in combination with reduced free T4 concentration. Subclinical hypothyroidism was defined as a TSH level .4.5 mIU/L in combination with a normal free T4 concentration. A TSH level ,0.45 mIU/L with normal free T4 levels was defined as subclinical hyperthyroidism. Overt hyperthyroidism was defined as a TSH level ,0.45 mIU/L with an elevated free T4 concentration (2).
Statistical analyses
We performed a two-stage individual participant data metaanalysis to allow for consistent definitions and analyses across the cohorts, increased analytical flexibility, and decreased complexity of the analyses (18, (23) (24) (25) (26) . In the first step, the cross-sectional and longitudinal associations between thyroid hormone status and anemia in each study cohort were estimated separately from supplied original study datasets with data on the participant level. In the second step, all effect estimates found in step one were pooled using random-effects models (DerSimonian and Laird) with inverse variance weighting.
For the cross-sectional association between thyroid hormone status and anemia at baseline, logistic regression models were constructed. Prospectively, we investigated the risk of developing anemia during follow-up using Cox regression models; participants with pre-existing anemia were excluded. The analyses were based on the thyroid function category at baseline. If a new case of anemia was identified, it was assumed that the anemia had developed halfway through the follow-up period.
Thyroid status was included as a categorical variable (overt hypothyroidism, subclinical hypothyroidism, subclinical hyperthyroidism, and overt hyperthyroidism), with euthyroidism as the reference group. All models were adjusted for age and sex. A P value for trend was obtained for both overt and subclinical hypothyroid and hyperthyroid categories. Subgroup analyses, including calculations of a P value for interaction, were performed separately for sex, age groups, and ethnicity.
In sensitivity analyses, we excluded all participants who used antithyroid medication or thyroid hormone replacement therapy at baseline or during follow-up. We also compared mean hemoglobin levels at baseline between thyroid status groups and differences in mean annual change in hemoglobin levels during follow-up between thyroid status groups using linear regression models. Additionally, we excluded all participants with a high level of C-reactive protein [(CRP); .20 mg/L] as a proxy for chronic inflammatory disease.
Data analyses were performed using IBM SPSS Statistics Version 23 and Review Manager 5.3 from the Cochrane Collaboration.
Results
For this study, individual participant data of 56,297 participants from 16 different cohorts participating in the Thyroid Studies Collaboration were available. At baseline, thyroid function (TSH and free T4) and hemoglobin measurements were available from 42,162 participants, of whom 459 (1.1%) had overt hypothyroidism, 2930 (6.9%) had subclinical hypothyroidism, 36,081 (85.6%) were euthyroid, 2386 (5.7%) had subclinical hyperthyroidism, and 306 (0.7%) had overt hyperthyroidism.
Baseline characteristics of the cohorts are presented in Table 1 . The overall median age of each cohort ranged from 46 to 85 years, and the overall percentage of women was 51.0%. More detailed information about the study participants is presented in Supplemental Tables 2 and 3 . The participants excluded because their thyroid function or hemoglobin measurement were not available had a median age ranging from 45 to 84 years; the percentage of women was 51.5%.
Cross-sectional analyses
At baseline, 4274 (10.1%) participants had anemia: 15.9% in the overt hypothyroid group, 11.6% in the subclinical hypothyroid group, 9.7% in the euthyroid group, 13.6% in the subclinical hyperthyroid group, and 11.1% in the overt hyperthyroid group. Participants with subclinical or overt hypothyroidism and subclinical or overt hyperthyroidism had increased odds of having anemia compared with participants with euthyroidism ( Table 2 ; Fig. 1 ). The pooled OR for the overt hypothyroid group was 1.84 (95% CI 1.35 to 2.50), 1.21 (1.02 to 1.43) for the group with subclinical hypothyroidism, 1.27 (1.03 to 1.57) for those with subclinical hyperthyroidism, and 1.69 (1.00 to 2.87) for those in the overt hyperthyroid group. We observed statistically significant trends from euthyroidism to hypothyroidism (i.e., from subclinical hypothyroidism to overt hypothyroidism; P = 0.01) and from euthyroidism to hyperthyroidism (i.e., from subclinical hyperthyroidism to overt hyperthyroidism; P = 0.04). When the analyses were stratified by sex, we observed no statistically significant differences (all P values for interaction .0.05) between men and women (Table 2) . Also, no statistically noteworthy differences were observed among different age categories or among white, black, or Asian participants.
Longitudinal analyses
In the longitudinal analyses, 25,466 participants from 14 cohorts were included, with a median follow-up time of 5.7 years (interquartile range 3.0 to 9.5). A total of 2423 participants developed anemia during follow-up (14.9 per 1000 person-years): 12.2% in the overt hypothyroid group, 12.0% in the subclinical hypothyroid group, 9.2% in the euthyroid group, 10.7% in the subclinical hyperthyroid group, and 8.7% in the overt hyperthyroid group (Table 3 ; Fig. 2 ). The pooled hazard ratios for the risk of developing anemia were 1.38 (95% CI 0.86 to 2.20) for the overt hypothyroid group, 1.18 (1.00 to 1.38) for the group with subclinical hypothyroidism, 1.15 (0.94 to 1.42) for the group with subclinical hyperthyroidism, and 1.47 (0.91 to 2.38) in the overt hyperthyroid group. We observed a statistically significant trend from euthyroidism to hypothyroidism (P = 0.02). No statistically significant trend was observed for euthyroidism to hyperthyroidism (P = 0.20). When the participants were stratified by sex, age, or ethnicity, these findings remained unchanged. Associations were more pronounced in those studies with a median follow-up $5 years (Supplemental Table 4 ).
Additional analyses
Cross-sectionally, hemoglobin levels (as a continuous variable) were lower (mean difference between 20.06 and 20.19 g/dL) in all groups compared with participants with euthyroidism (Supplemental Table 5 ). Prospectively, no differences in mean annual change in hemoglobin levels were observed among the thyroid hormone status groups (Supplemental Table 6 ). Similar results were observed when analyses were stratified on sex. In addition, sensitivity analyses excluding participants who used thyroid hormone medication or with high levels of CRP yielded higher ORs in line with the unrestricted results but with wider CIs (Supplemental Tables 7 and 8) .
For all main analyses, I 2 statistics remained ,40%
(Supplemental Tables 9 and 10) , and, in combination with size and direction of effects, statistical heterogeneity was deemed low to negligible (27) .
Discussion
In this individual participant data meta-analysis, we observed a cross-sectional relation between thyroid 
Data are pooled hazard ratio (95% CI) unless otherwise noted. Results were obtained by logistic regression analysis, adjusted for age (if applicable) and sex. a P for trend: overt hyperthyroidism to euthyroidism, P = 0.01; euthyroidism to overt hyperthyroidism, P = 0.04.
b Reference group is ,50 y.
c Reference group is white.
d Only data from CHS, Health ABC, and PREVEND.
e Only data from LASA, Nagasaki, PREVEND, and Rotterdam.
f Only data from LASA, PREVEND, and Rotterdam. Figure 1 . The pooled ORs of the risk of having anemia at baseline with the 95% CI and P value for trend. Logistic regression models corrected for age and sex; reference group is euthyroidism. function and anemia; higher odds of anemia were observed in participants with both overt and subclinical hypothyroidism as well as overt and subclinical hyperthyroidism. In addition, reduced thyroid function at baseline showed a trend of increased risk of developing anemia during follow-up. The longitudinal association between overt and subclinical hyperthyroidism and the risk of developing anemia did not reach statistical significance. Prospectively, no differences in mean annual change in hemoglobin levels were observed among the thyroid hormone status groups.
The findings in the current individual participant data meta-analysis build on findings from earlier studies in which thyroid dysfunction was associated with abnormal red blood cell indices (11) (12) (13) . In this study, thyroid dysfunction, whether overt or subclinical hypothyroidism and hypothyroidism, was associated with slightly lower hemoglobin levels. Given the small difference in hemoglobin levels among thyroid function groups, the contribution of thyroid dysfunction on low hemoglobin levels or anemia may be small. It remains to be assessed in a randomized controlled trial whether treatment of (subclinical) hypothyroidism is effective in reducing anemia to further decide whether the findings are thought to be clinically relevant and whether these should influence practice and policies. Christ-Crain et al. (28) showed that erythropoietin levels increased after thyroxin treatment in patients with subclinical hypothyroidism. In addition, a number of studies have also shown a beneficial effect of thyroid hormone treatment in patients with hypothyroidism on erythropoietin levels (12, 15, 16) .
There are numerous types of anemia that can be classified according to whether the anemia is primarily 
Data are pooled hazard ratio (95% CI) unless otherwise noted. Results were obtained by Cox regression analysis, adjusted for age (if applicable) and sex. a P for trend: overt hyperthyroidism to euthyroidism, P = 0.02; euthyroidism to overt hyperthyroidism, P = 0.20.
c P value for interaction (P , 0.05).
d Reference group is white.
e Only data from CHS, Health ABC, and PREVEND.
f Only data from LASA, Nagasaki, PREVEND, and Rotterdam.
g Only data from LASA, PREVEND, and Rotterdam. Figure 2 . The pooled hazard ratios of developing anemia during follow-up in the thyroid function groups with the 95% CI and P value for trend. Cox regression models corrected for age and sex; reference group is euthyroidism.
the result of blood loss, deficits in the production of healthy erythrocytes, or by reduced erythrocyte survival. Currently, it is unclear what mechanisms exactly allow thyroid function and erythropoiesis to be linked pathophysiologically and how both ends of the thyroid disease spectrum might lead to an anemic state. However, for subclinical and overt hyperthyroidism, several pathways have been proposed. Hyperthyroidism might be associated with anemia via reduced erythrocyte survival due to altered iron metabolism and utilization, enhanced oxidative stress, and increased hemolysis (29, 30) . Thyroid hormones stimulate energy metabolism, resulting in an enhanced requirement of oxygen delivery to the tissues speeding up destructive processes. For subclinical and overt hypothyroidism, there is accumulating evidence that indicates low thyroid function may be causally related to anemia via deficits in the production of healthy erythrocytes, although the underlying mechanisms by which thyroid hormones and TSH may lead to anemia are not fully understood (31) . T3, T4, and TSH may play a direct role in erythropoiesis (32) . For instance, both T3 and T4 are involved in the regulation of hematopoiesis by influencing erythroid precursor proliferative capacity (33) . In addition, a direct b2-adrenergic receptor-mediated stimulation of red cell precursors by T4 has been shown (34) . T4 has also been found to stimulate the initiation and completion of hemoglobin protein chains in vitro and to enhance red blood cell formation (5). Thyroid hormones were also shown to promote erythropoiesis by increasing the production of erythropoietin by the kidneys (35) . Furthermore, there is evidence that thyroid hormones affect iron transport and utilization. TSH could affect hematopoiesis by binding to a functional TSH receptor, which can be found in erythrocytes and some extrathyroidal tissues (10) . Another explanation for the co-occurrence of low thyroid function and anemia is that there are common causes for abnormal thyroid status and anemia. Chronic (inflammatory) diseases, malnutrition, and malabsorption may all result in reduced thyroid status as an adaptive response to energetic deficits. In addition, malnutrition and malabsorption may cause deficiencies of micronutrients that are crucial for erythropoiesis, like iron, vitamin B12, and folate, as well as iodine deficiency, which is crucial for normal thyroid function. Interestingly, iron deficiency, which is the most common cause of anemia, was also found to decrease the activity of thyroid peroxidase, an iron-containing enzyme involved in the synthesis of thyroid hormones (36) .
Strengths of the current individual participant data meta-analysis are the inclusion of individual participant data of large cohort studies from across the globe. The availability of individual participant data allowed us to choose clinically relevant categories of thyroid function and anemia, standardize these definitions, and perform several standardized subgroup analyses.
An individual participant data meta-analysis of welldesigned observational studies can be considered an important tool in assessing causality. When studying causality, the nine considerations of Hill in 1965 (37) can be used as a checklist. In our study, many of these considerations are met. Although the individual study cohorts and individual subgroups may have been small, we had sufficient power to study the associations in this pooled analysis because of the increased combined sample size. Because multiple studies were included, we could also study consistency in the results of the different cohorts (e.g., effect estimates all pointing in the same direction); the low level of heterogeneity also aids in considering a causal relation. In addition, the availability of the individual participant data allowed us to define identical subgroups for each study in a biological gradient, from overt hypothyroidism to overt hyperthyroidism. The availability of prospective observational data are also in compliance with the fourth consideration of temporality; in 14 studies, a baseline measurement of the determinant (thyroid function) and (baseline and) follow-up measurements of the outcome of interest (hemoglobin) were available. Therefore, our pooled analysis of observational studies satisfies multiple criteria of Hill. However, it remains to be assessed in a well-designed, randomized controlled trial with a considerable number of participants with (subclinical) hypothyroidism if treatment is effective in reducing anemia. Further analysis of the data from two welldesigned, randomized controlled trials for subclinical hypothyroidism in older persons [TRUST and IEMO Thyroid Trial (38, 39) ] could be a first attempt at uncovering the clinical relevance of thyroid influences on hemoglobin levels.
Some limitations of this study have to be acknowledged as well. First, a limitation of this pooled analysis is that TSH and free T4 were only measured once at baseline. Because subclinical hypothyroidism has been shown to normalize in one-third of cases (40) , in guidelines, it is often recommended that measurements of these parameters are repeated. Unfortunately, repeated TSH and free T4 measurements were not available in many cohorts. Erroneously classifying patients with euthyroidism based on one measurement may have led to an underestimation of the associations found. Second, the statistical power was more limited in the longitudinal models than in the baseline, cross-sectional analysis. The association between overt and subclinical hyperthyroidism and the risk of developing anemia did not reach statistical significance, but the results of the longitudinal analyses followed a similar pattern. Third, we did not apply age-adjusted reference ranges as per current consensus and usual practice. However, evidence in favor of age-specific TSH reference ranges is starting to accumulate (41); so, too, is evidence to the contrary (42) (43) (44) . This is an important topic of future research. Fourth, we performed sensitivity analyses excluding participants with high CRP levels as a proxy for chronic diseases that might predispose to anemia, but this only excluded diseases associated with inflammation. Particularly in the group of participants with subclinical hypothyroidism, the possibility of the presence of nonthyroidal illness cannot be fully excluded. As a result, possible residual errors caused by residual bias and confounding may have deflated the results. Unfortunately, information on additional potential confounding factors, like thyroid medication dose titrations, other diseases relating to anemia (cancer, chronic kidney disease, leukemia, gastric ulcers, arthritis, or chronic obstructive pulmonary disease), menopausal state, nonthyroidal illness, concomitant medications, and iron or vitamin supplements, was not available for most cohorts.
In conclusion, we observed higher odds of anemia in both participants with hypothyroid and hyperthyroid function. In addition, reduced thyroid function at baseline showed a trend of increased risk of developing anemia during follow-up. It remains to be assessed in a randomized controlled trial whether treatment of (subclinical) hypothyroidism is effective in reducing anemia.
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